Zimmer Biomet Plans to Repurchase Up to $1B in Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2026
0mins
Zimmer Biomet announced that it now anticipates repurchasing up to $1B of its common stock during fiscal year 2026, a $250M increase from the company's prior assumption.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZBH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZBH
Wall Street analysts forecast ZBH stock price to rise
18 Analyst Rating
4 Buy
11 Hold
3 Sell
Hold
Current: 85.310
Low
88.00
Averages
100.47
High
120.00
Current: 85.310
Low
88.00
Averages
100.47
High
120.00
About ZBH
Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zimmer Biomet Declares Quarterly Dividend and Increases Buyback Target
- Quarterly Dividend Declaration: Zimmer Biomet has declared a quarterly dividend of $0.24 per share, consistent with previous distributions, payable on July 31, which underscores the company's stable cash flow and commitment to shareholder returns.
- Dividend Yield: The forward yield of 1.12% reflects the company's attractiveness in the current market environment, potentially drawing in more investors seeking stable income.
- Increased Buyback Target: Zimmer Biomet has raised its share repurchase target to up to $1 billion, expected to be completed by year-end, a move aimed at enhancing earnings per share and shareholder value while signaling confidence in future growth.
- Upgraded Earnings Outlook: The company has adjusted its 2026 adjusted EPS forecast to $8.40-$8.55 and plans to hire over 200 robotics clinical personnel by the end of 2027, indicating its strategic focus on expansion and innovation in the medical technology sector.
See More
Zimmer Biomet Announces Quarterly Cash Dividend
- Quarterly Cash Dividend: Zimmer Biomet's Board of Directors has approved a cash dividend of $0.24 per share for Q2 2026, payable on or about July 31, 2026, reflecting the company's commitment to returning value to shareholders.
- Record Date for Shareholders: The record date for this dividend is June 25, 2026, ensuring that investors holding shares by this date will receive the dividend, which enhances investor confidence in holding the stock.
- Company Background: Zimmer Biomet is a global leader in medical technology with over 90 years of industry experience, dedicated to enhancing patient experiences through innovative products and digital technologies, further solidifying its market position.
- Global Business Reach: The company operates in over 25 countries and sells products in more than 100 countries, showcasing its strong global market influence and potential for continued growth.
See More
Zimmer Biomet Plans $1B Stock Buyback in 2026
- Increased Buyback Plan: Zimmer Biomet announced its intention to repurchase up to $1 billion of common stock in fiscal year 2026, a $250 million increase from previous estimates, indicating strong confidence in future cash flows.
- Stable Authorization: All repurchases are expected to occur under the existing $1.5 billion share repurchase authorization approved by the Board in February 2026, reflecting the company's robust capital management strategy.
- Earnings Outlook Raised: The company raised its adjusted EPS forecast for 2026 to $8.40-$8.55, showcasing optimism about future performance, which may attract more investor interest in its stock.
- Workforce Expansion Goals: Zimmer Biomet aims to hire over 200 robotics clinical personnel by the end of 2027, intending to enhance its competitiveness in the medical robotics sector and drive long-term growth.
See More
Zimmer Biomet Plans $1 Billion Stock Buyback
- Increased Buyback Plan: Zimmer Biomet has announced an increase in its stock buyback plan to up to $1 billion for fiscal year 2026, a $250 million rise from previous estimates, reflecting the company's confidence in its financial health.
- Authorization Remains Unchanged: The buyback will occur under the existing $1.5 billion share repurchase authorization approved by the Board, indicating the board's recognition and support of current market conditions.
- Market Reaction Anticipated: The company may repurchase shares in the open market or enter into structured repurchase agreements with third parties, which is expected to positively impact stock prices and bolster investor confidence.
- Capital Allocation Flexibility: The timing and actual amount of repurchases will depend on market conditions, stock price, and capital availability, demonstrating the company's flexibility and foresight in capital management.
See More
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
Market Resembles 1999 but with Greater Punishment for Stocks
- Increased Market Punishment: Cramer highlighted that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating investor disappointment in healthcare tech firms.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, the market has become increasingly bifurcated, with investors flocking to artificial intelligence stocks while aggressively selling off others.
- Healthcare Tech Companies Struggling: Danaher has seen a 27% decline in stock price, and Cramer noted that several medical technology firms, including Boston Scientific and Medtronic, have hit new lows, reflecting a cold market attitude towards non-tech stocks.
- AI Hype and Market Extremes: Cramer cautioned that while investors are overly enthusiastic about AI stocks, the current market dynamics are far more extreme than in 1999, with some hated stocks being excessively punished and loved stocks being excessively favored.
See More
Zimmer Biomet Declares Quarterly Dividend and Increases Buyback Target
- Quarterly Dividend Declaration: Zimmer Biomet has declared a quarterly dividend of $0.24 per share, consistent with previous distributions, payable on July 31, which underscores the company's stable cash flow and commitment to shareholder returns.
- Dividend Yield: The forward yield of 1.12% reflects the company's attractiveness in the current market environment, potentially drawing in more investors seeking stable income.
- Increased Buyback Target: Zimmer Biomet has raised its share repurchase target to up to $1 billion, expected to be completed by year-end, a move aimed at enhancing earnings per share and shareholder value while signaling confidence in future growth.
- Upgraded Earnings Outlook: The company has adjusted its 2026 adjusted EPS forecast to $8.40-$8.55 and plans to hire over 200 robotics clinical personnel by the end of 2027, indicating its strategic focus on expansion and innovation in the medical technology sector.
See More
Zimmer Biomet Announces Quarterly Cash Dividend
- Quarterly Cash Dividend: Zimmer Biomet's Board of Directors has approved a cash dividend of $0.24 per share for Q2 2026, payable on or about July 31, 2026, reflecting the company's commitment to returning value to shareholders.
- Record Date for Shareholders: The record date for this dividend is June 25, 2026, ensuring that investors holding shares by this date will receive the dividend, which enhances investor confidence in holding the stock.
- Company Background: Zimmer Biomet is a global leader in medical technology with over 90 years of industry experience, dedicated to enhancing patient experiences through innovative products and digital technologies, further solidifying its market position.
- Global Business Reach: The company operates in over 25 countries and sells products in more than 100 countries, showcasing its strong global market influence and potential for continued growth.
See More
Zimmer Biomet Plans $1B Stock Buyback in 2026
- Increased Buyback Plan: Zimmer Biomet announced its intention to repurchase up to $1 billion of common stock in fiscal year 2026, a $250 million increase from previous estimates, indicating strong confidence in future cash flows.
- Stable Authorization: All repurchases are expected to occur under the existing $1.5 billion share repurchase authorization approved by the Board in February 2026, reflecting the company's robust capital management strategy.
- Earnings Outlook Raised: The company raised its adjusted EPS forecast for 2026 to $8.40-$8.55, showcasing optimism about future performance, which may attract more investor interest in its stock.
- Workforce Expansion Goals: Zimmer Biomet aims to hire over 200 robotics clinical personnel by the end of 2027, intending to enhance its competitiveness in the medical robotics sector and drive long-term growth.
See More
Zimmer Biomet Plans $1 Billion Stock Buyback
- Increased Buyback Plan: Zimmer Biomet has announced an increase in its stock buyback plan to up to $1 billion for fiscal year 2026, a $250 million rise from previous estimates, reflecting the company's confidence in its financial health.
- Authorization Remains Unchanged: The buyback will occur under the existing $1.5 billion share repurchase authorization approved by the Board, indicating the board's recognition and support of current market conditions.
- Market Reaction Anticipated: The company may repurchase shares in the open market or enter into structured repurchase agreements with third parties, which is expected to positively impact stock prices and bolster investor confidence.
- Capital Allocation Flexibility: The timing and actual amount of repurchases will depend on market conditions, stock price, and capital availability, demonstrating the company's flexibility and foresight in capital management.
See More
Market Punishes Stocks More Aggressively, Tech Stocks Favored
- Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
- Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
- Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
See More
Market Resembles 1999 but with Greater Punishment for Stocks
- Increased Market Punishment: Cramer highlighted that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating investor disappointment in healthcare tech firms.
- Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, the market has become increasingly bifurcated, with investors flocking to artificial intelligence stocks while aggressively selling off others.
- Healthcare Tech Companies Struggling: Danaher has seen a 27% decline in stock price, and Cramer noted that several medical technology firms, including Boston Scientific and Medtronic, have hit new lows, reflecting a cold market attitude towards non-tech stocks.
- AI Hype and Market Extremes: Cramer cautioned that while investors are overly enthusiastic about AI stocks, the current market dynamics are far more extreme than in 1999, with some hated stocks being excessively punished and loved stocks being excessively favored.
See More
